When Private Equity Meets Structured Finance
Collateralized fund obligations – CFOs, not to be confused with chief financial officers – are a niche corner of structured finance that most limited partners have never had to think about directly. They work by pooling interests in private equity or private credit funds, then issuing tranched debt and equity notes against that pool, much like a CLO does with leveraged loans. The senior tranches get paid first and carry relatively modest yields. The equity tranche absorbs losses first and can produce outsized returns if the underlying funds perform. The mechanics are familiar to anyone who has spent time in credit markets. The application to private fund interests is newer, and the implications for LP allocators are only beginning to surface.
What makes CFOs worth watching now is not the structure itself but who is using it, and why.
A growing number of large asset managers with diversified private equity platforms have begun sponsoring CFOs as a way to recycle capital, generate fee income, and provide liquidity options to fund investors who might otherwise be stuck waiting for natural distributions. For the sponsor, it is an elegant solution. For the LP sitting on the other side of the table – either as a buyer of CFO notes or as an investor in a fund whose interests are being securitized – the picture is more complicated.
What LP Allocators Are Starting to Ask
The scrutiny emerging among LP allocators is not about the legality or novelty of CFOs. It is about transparency and alignment. When a GP securitizes LP interests through a CFO, those interests are effectively pledged as collateral. Depending on the structure, this can affect voting rights, consent requirements, and the GP’s incentives around fund management decisions. An allocator who invested directly into a fund expecting a certain governance relationship may find that relationship looks different once their interests are wrapped into a securitization vehicle they had no direct say in.
Fund documents have historically been written without CFOs in mind. Many partnership agreements include language permitting the GP to create or participate in securitization structures without explicit LP approval, particularly when the GP itself retains the equity tranche of the CFO. That retention is often framed as alignment – the GP keeps the first-loss piece – but it also means the GP now has a leveraged exposure to fund performance that can create pressure to exit positions faster or hold longer than pure fund economics would suggest. Neither outcome is inherently bad, but neither is it neutral from an LP’s perspective.
The more pointed concern is mark sensitivity. CFOs backed by private equity interests require periodic valuations of the underlying fund stakes. Those valuations are largely controlled by the GP. When a CFO has leverage covenants tied to NAV, there is a structural incentive – not necessarily acted on, but present – for GPs to manage reported valuations in ways that serve the securitization vehicle. Allocators who have spent years scrutinizing GP valuation practices in direct fund contexts are now asking whether CFO structures add another layer of opacity to an already opaque process.
The Appeal Hasn’t Gone Anywhere
None of this scrutiny means CFOs are going away. For certain institutional buyers, the senior notes on a well-constructed CFO offer something genuinely difficult to find elsewhere: investment-grade-rated exposure to private equity cash flows with defined seniority protections. Insurance companies and pension funds with specific rating requirements have found CFO notes useful in ways that direct fund investments cannot satisfy. The yield pickup over comparably rated corporate debt can be meaningful, and the diversification across multiple fund vintages and strategies provides a buffer against single-fund underperformance. The structural appeal is real, and it is not going to be argued away by governance concerns alone.
The equity tranche is a different conversation. Buyers of CFO equity are essentially taking leveraged exposure to a portfolio of fund interests, with all the illiquidity and valuation uncertainty that entails, plus the additional complexity of the securitization wrapper. The return potential can be significant – leverage amplifies gains just as readily as it amplifies losses – but the due diligence required to underwrite CFO equity well is substantially more intensive than buying into the underlying funds directly. An allocator needs to understand not just the funds in the pool but the structure’s waterfall, the coverage tests, the reinvestment provisions, and the GP’s role across all of it. That is a different skill set than most private equity teams have built.
The market for leveraged loan CLOs offers a useful reference point. CLO technology matured over decades as investors, rating agencies, and managers worked through alignment questions, disclosure standards, and covenant design. CFOs are at an earlier stage of that same process. The structures being issued today will not look identical to the structures issued five years from now, once more allocators have pushed back on documentation terms and regulators have taken a harder look at disclosure requirements.
Where the Pressure Builds
The real test will come from institutional LPs large enough to negotiate directly with GPs before committing to funds that may later be included in CFO pools. Some large sovereign wealth funds and public pension plans have begun requesting side letter provisions that require GP notification – and in some cases approval – before fund interests are securitized. Whether those provisions hold up under legal challenge, and whether smaller LPs without negotiating leverage will ever get equivalent protection, remains an open question that the market has not yet answered cleanly.
